About Inventprise
Inventprise is leveraging its innovative platform technology to develop vaccines against infectious diseases with an initial focus on invasive pneumococcal disease.
About Inventprise
Inventprise platform technologies are designed to enable high valent vaccines to induce broad, robust, and durable protection against pathogenic strains of infectious diseases.
In addition to its lead candidate, the 25-valent pneumococcal conjugate vaccine, Inventprise has a robust pipeline of investigational vaccines including candidates to prevent group B streptococcus (GBS), Shigella and Klebsiella.
Inventprise was founded by Subhash Kapre, PhD in 2012 to advance novel, highly impactful vaccines using proprietary technology, with the initial goal of providing lifesaving interventions globally.
Our mission is to empower people to live healthy lives by inventing better vaccines.
We leverage the best of vaccine technology, science, and manufacturing to prevent infectious disease
Our Focus is On Science
Together with our community of collaborators, Inventprise engages in cutting-edge research bringing incisive scientific insights and novel products to global populations in need of important, life-saving vaccines.
Our efforts have led to over fifty patents, many on proprietary approaches and methods in the development of highly immunogenic vaccines.
With multiple partners and collaborations, and a large portfolio of vaccine candidates, our aim is to remain true to our science, continue to innovate and deliver better vaccines to the world.
Executive Leadership
Subhash Kapre, PhD
Founder & Executive Chairman
Subhash Kapre, PhD, is the Founder and Executive Chairman of Inventprise. His passion for improving lives through the elimination of infectious diseases began more than five decades ago, and remains stronger than ever today. Holding 70 patents, Dr. Kapre is considered a thought leader in vaccine technology and an internationally renowned expert in both bacterial and viral vaccines. He has been instrumental in driving multiple vaccines from discovery to licensure, including MenAfriVac®. Dr. Kapre’s expertise spans not only vaccine discovery and R&D, but also manufacturing.
Prior to coming to the U.S., Dr. Kapre had an impressive 40-year career at the Serum Institute of India, the world’s largest vaccine manufacturer. He served in multiple senior executive roles, including Board Executive Director. After moving to the U.S., Dr. Kapre discovered he still had a passion for protecting those most in need, and after serving as a consultant for other companies, he decided to create Inventprise in 2012. Under his leadership, Inventprise has grown from two to more than 200 employees, has four facilities, and has state-of-the-art large-scale manufacturing capabilities to achieve its vision of safeguarding lives worldwide.
Subhash Kapre, PhD
Founder & Executive Chairman
Yves Leurquin, Eng., MS President & CEO
Yves Leurquin leads Inventprise with a focus on partnerships, capital formation and structural growth. Before joining Inventprise, Yves Leurquin was Global Head of Pricing and Tender Management for Takeda’s Vaccine Business Unit. He joined the newly created Takeda Vaccine Business Unit at its inception where he led the Asia Pacific Region and then the European Region. Yves also held corporate board positions, at Takeda Vaccine Internationals. Additionally, Yves prior experience included EVP International and Government Affairs at Johnson & Johnson (Crucell) with oversight of relations with the United Nations organizations as well as business responsibility for Latin America, Middle East, Africa and Asia where he led a multi-functional team of marketing, sales and government affairs professionals generating two third of the group’s vaccine revenue. While at J&J Yves Leurquin organized the development and international launch of the first liquid Penta vaccine, winning supply contracts with UNICEF and PAHO and rapidly achieving a dominant market share. Prior to joining Johnson &Johnson, Yves was with the vaccine division of GlaxoSmithKline, holding progressively responsible positions over a 10-year tenure.Yves Leurquin, Eng., MS
President & CEO
Pradip Ghate, MS, DMM
Chief Operating Officer
Pradip Ghate is an industry expert in large-scale vaccine and injectables manufacturing. With nearly four decades of global experience, he is adept at overseeing all aspects of development, production, and operations. He started his distinguished career at the Serum Institute of India, where the company grew by 10X during his tenure, and today remains one of the world’s largest vaccine manufacturers. After moving to North America in 1999, Pradip has served in a variety of positions—from Fortune 500 companies to biotech startups—including Hemosol, Cardinal Health, Catalent, and most recently, Inventprise. As Chief Operating Officer, Pradip oversees the day-to-day administrative and operational functions of the business. He also facilitated the build-out of the company’s best-in-class large-scale manufacturing facility, which recently opened in Woodinville, WA. As a Certified Lean Six Sigma Black Belt, operational excellence is at the center of everything he does, and his vision has been a driving force in the steady growth of Inventprise.
Pradip Ghate, MS, DMM
COO
Sybil Tasker MD, MPH, FIDSA Chief Medical Officer
Sybil Tasker is Chief Medical Officer at Inventprise Inc. and is an infectious disease physician with over 30 years experience in clinical practice, global public health and vaccine and antimicrobial clinical development. She has had 2 prior biotech CMO positions, most recently at Codagenix, where she brought multiple live attenuated virus vaccines into the clinic. While in her previous position at Altimmune, she led clinical, regulatory and quality for 3 vaccine programs during which time the company became publicly listed through reverse merger. A prior career US Navy medical officer, Sybil was head of infectious diseases at the National Naval Medical Center in Bethesda MD and served as DOD regional director for PEPFAR funded programs in Africa. Her initial position in industry was for a global contract research organization, planning execution of Phase 1-4 clinical studies for antibiotics, antivirals and vaccines for a wide variety of pharma and biotech clients. Sybil holds a California medical license and is a fellow of the American College of Physicians and Infectious Diseases Society of America, and is a diplomate. She earned AB degree in Biochemistry from Princeton University, an MD from Columbia University and MPH from Johns Hopkins University.Sybil Tasker, MD, MPH, FIDSA
CMO
Jeff Wilson Chief Financial Officer
Jeff Wilson is the Inventprise Chief Financial Officer. He originally joined the company in June 2023 to successfully lead our Partnership and Enterprise Resource Planning (ERP) efforts. In October 2024, he assumed the role of CFO, and will be leading the ongoing efforts to develop and grow our business worldwide. Jeff brings a wealth of global financial leadership experience, having previously served in CFO roles at Command Center, Acumatica, and Microvision. He also has deep experience in biotech diagnostics, devices, and services, leading all aspects of strategic planning, Finance and Accounting, and Investor Relations at TwinStrand Biosciences and Quorum Review.Jeff Wilson
CFO
Rachael Moss, MBA, SPHR Chief People Officer
Rachael is a Chief People Officer at Inventprise Inc. and is a human resources leader with over 20 years of experience across multiple domains and industries. Rachael has held leadership roles in multiple companies, most recently at Commerce fabric Inc. where she was Vice President of Talent, responsible for leading several people transformational efforts to help support the company’s rapid growth. Before Commerce fabric, she held various human resources roles at Liberty Mutual, Equinix, T-Mobile, Amazon and Ernst & Young. Rachael holds a BA from the University of Illinois at Chicago, an MBA from the Keller Graduate School of Management and an SPHR certification. She also proudly serves as a board member of the Friends of the Seattle Public Library, a non-for-profit organization dedicated to elevating the library’s outreach while inspiring the love of reading in Seattle’s communities.Rachael Moss, MBA,SPHR
CPO
Management Team
Indah Andi-Lolo, MSc. PMP
VP of Portfolio Management
Indah Andi-Lolo is the Vice President of Portfolio Management at Inventprise. She brings over 15 years of experience in leading and managing complex vaccine development programs across clinical, regulatory, and manufacturing space within the pharmaceutical industries and nonprofit organizations.
Prior to joining Inventprise, Indah led vaccine development project teams at PATH working on a portfolio of projects funded by the Bill & Melinda Gates Foundation and the Coalition for Epidemic Preparedness Innovations (CEPI). Her industry background included serving as the Global Program Manager at Novartis Vaccines (now GSK) in Siena (Italy) and in Singapore, before taking on the responsibility as the Director of Project Management and Planning at Takeda Vaccines Singapore.
Indah holds post graduate degrees in International Business and Biotechnology and is a certified Project Management Professional.
Indah Andi-Lolo, MSc. PMP
VP of Portfolio Management
Anup Datta, PhD
VP of Bacterial Vaccines
Dr. Anup Datta is an accomplished professional with 20 years of comprehensive experience in bacterial and protein – sub-unit vaccines, development and technology transfer from concept to clinical thru licensure and commercial manufacturing. Anup is recognized as an industry leader in conjugate vaccine development, and played a pivotal leadership role, as a co-inventor and developer of several conjugate vaccines. His broad experience comprises of process & analytical chemistry, biochemistry, including bioconjugation, quality and CMC regulatory. He holds a PhD in the field of polysaccharide conjugate vaccine and has also worked on several NIH/USA funded projects as principal/co-investigator. Anup has experience working at various senior management level position in the US as well as India, having worked in several premier WHO pre-qualified vaccine development and manufacturing companies.
Anup Datta, PhD
VP of Bacterial Vaccines
Ivan Olave, PhD
VP of Viral Vaccines
Dr. Ivan Olave has more than 20 years of experience as biochemist with thorough understanding of vaccine development, small drug development, target selection and validation, pre-clinical studies, protein biochemistry and gene regulation. He is skillful in management of projects and personnel, and technology assessment and licensing. Ivan received a Ph.D. in Biochemistry from Rutgers University in New Jersey, and did post-doctoral work at Stanford University in California.
Ivan Olave, PhD
VP of Viral Vaccines
Mark Silverberg
VP of Quality
Mark Silverberg has served as the head of Quality since 2019, he is responsible for quality systems, Quality Assurance / Quality Control, microbiological programming, validation, training and related support functions. Mark has 25+ years of senior management and C-Suite experience, dealing with both domestic and international business environments and regulated markets. Mark has held senior leadership positions in both large and small biotechnology companies, including global Quality Assurance: operations, R&D regulatory affairs, compliance, logistics and 3rd party alliances.
Mark Silverberg
VP of Quality
Philip Cherian
VP of Material Management & Engineering Innovations
As an entrepreneur and global manager for over 30 years with both small and large companies, Philip has good knowledge of BioProcess Engineering, BioPharma Processes, cGMP and regulatory requirements in the BioPharmaceutical industry. He has worked on multiple projects in the US, Europe, and Asia as Founder and Managing Director of Sartorius in India, Sr. Vice President for B.Braun Biotech based in Germany, and as President and General Manager of Sartorius BBI Systems subsidiary in the US. In his ongoing assignment as Director of Materials and Process Innovation Engineering with Inventprise, he works with our scientists, management and engineering team to help design equipment from lab scale to full production scale. Philip has an MBA from a leading European Business School (IMD) apart from a BS degree in Chemistry, Physics and Mathematics.
Philip Cherian
VP of Material Management & Engineering Innovations
Manoj Kumar, PhD
VP of Manufacturing Science & Technology
Dr. Manoj Kumar is a proven leader in vaccine industry with more than 20 years of academic and industry experience in field of microbiology, vaccinology, and epidemiology. Dr. Kumar has extensive experience in early to late-stage vaccine R&D programs, including technology transfer of projects along the continuum from academic labs to industry research labs, to development labs, and on to manufacturing and quality control lab settings.
Prior to joining Inventprise, he served in leadership positions in various vaccine R&D and manufacturing organizations in India namely, Chief Scientific Officer of Hester Biosciences Ltd., Ahmedabad; Associate Vice President-R&D at Biological E Ltd., Hyderabad; Senior Director-R&D at MSD Welcome Trust Hilleman Labs, New Delhi, and Head of Immunobiology and Molecular Research Lab at Serum Institute of India Research Foundation, Pune.
Dr. Kumar holds a Ph.D. in Veterinary Bacteriology and an Advanced Diploma in Business Administration. He has 18 patent applications, 15 peer reviewed publications, 2 book chapters and 3 whole genome sequences in his name. He has presented in more than 40 scientific conferences and has reviewed for 14 scientific journals. He has received more than 20 national and international awards and honors.
Manoj Kumar, PhD
VP of Manufacturing Science & Technology
Ramesh Shanbhag
VP of Facilities & Engineering
Ramesh Shanbhag has over 30 years of extensive experience in designing and implementing, facility and engineering projects in the pharmaceutical and biotech industry. Ramesh has successfully executed projects in 33 countries complying with USFDA, WHO and EU QUALITY & GMP regulations. Ramesh has experience in leading multidisciplinary multi-nationality project teams for successful execution of projects. Ramesh has a Professional Engineer (PE) certification from the U.S., and a Chartered Engineer(CEng) certification from the European Union.
Ramesh Shanbhag, PE. CEng.
VP of Facilities & Engineering
Kapil Kapre
Director of Project Management & Automation
Kapil Kapre is responsible for Inventprise’s automation and long-term digital transformation strategy. Most recently, he has been hands-on with process equipment design, qualification, commissioning and verification activities for Inventprise’s commercial production facility. In the past at Inventprise, he has designed and built prototype pilot-scale automated equipment for processing bulk material. In addition, he has been the project manager for IT and digital initiatives at Inventprise
Kapil Kapre
Director of Project Management & Automation
Raymond Bevers
Director of Manufacturing
Raymond Bevers is responsible for Manufacturing Operations following current Good Manufacturing Practice (cGMP) standards. He also oversees long-term production scheduling and logistics. Raymond joins us from a global Contract Development and Manufacturing Organization (CDMO), with experience providing manufacturing services for protein-based biologics and advanced therapies. His responsibilities included mammalian, microbial, and adjuvant production lines. Raymond brings hands-on experience with both single use and stainless-steel technologies, new facility startup, and fill finish. He also has a successful track record of advancing clinical stage products to FDA approval.
.
Raymond Bevers
Director of Manufacturing
Board of Directors
Subhash Kapre, PhD
Chairman & Founder
Inventprise’s Founder and Executive Chairman of the Board is Subhash Kapre, PhD. His experience encompasses multiple senior executive vice president positions at Serum Institute of India Pvt. Ltd. (SIIPL), which measured by volume, is the world’s largest vaccine manufacturer. During his four-decade tenure at SIIPL, Subhash held multiple functional leadership positions in R&D, manufacturing, and vaccine discovery.
Subhash is a thought leader in rDNA technology, an internationally renowned expert in both bacterial and viral vaccines and has led certification of WHO- Prequalification (regulatory approval) for large scale manufacturing. He held board positions at Akorn, and Serum Institute of India, where he was board, executive director.
Subhash has a history of driving multiple vaccines from discovery, into development and through licensure for infectious diseases, including MenAfriVac® and Pneumosil®, conjugate vaccines which together will represent over 500M aggregate doses delivered by 2022. Subhash holds over 70 patents and founded Inventprise in 2012 to continue his career long mission to provide vaccines for those most in need.
Niranjan Bose, PhD
Board Co-Chairman
Dr. Niranjan Bose is the Managing Director of Health & Life Sciences at Gates Ventures, where he serves as the Science Advisor to Mr. Bill Gates. Prior to this appointment, Dr. Bose was the Chief of Staff to the President of the Global Health Program at the Bill & Melinda Gates Foundation. Prior to joining the Bill & Melinda Gates Foundation, he was with Strategic Decisions Group (and SDG Life Sciences), where he was a Senior Consultant and assisted clients in the pharmaceutical and biotechnology industries with strategy development, company valuations, portfolio management frameworks, revenue forecasting, and competitive assessments.
Ralf Clemens, MD, PhD
Board Director
Dr. Ralf Clemens has held executive positions in several leading multinational corporations, such as GSK, Novartis Vaccines, and Takeda, and has developed and brought to licensure more than 25 different vaccines globally.
Dr. Clemens is currently a member of the Board of Trustees of the International Vaccine Institute (IVI), a leading global vaccinology organization initiated by the United Nations Development Programme, a Member of the Selection Committee of Global Health Innovative Technology (GHIT) Fund from Japan, and an external Scientific Advisor to the Bill & Melinda Gates Foundation. He is the author of more than 200 publications and 250 presentations in the fields of vaccines, immunization, and tropical medicine.
H. Stewart Parker, MBA
Board Director
Ms. Parker has served as a Principal at Parker BioConsulting, a biotechnology consulting firm, since January 2009. From March 2011 to June 2014, Ms. Parker served in various roles at the Infectious Disease Research Institute, a not-for-profit global health research institute, including as its Chief Executive Officer, strategic advisor, and a member of the board of directors. Prior to that, Ms. Parker has also served in various roles of leadership at biopharmaceutical companies since 1992, including as Chief Executive Officer of Targeted Genetics Corporation, a publicly-traded biopharmaceutical company, which she founded. Since 2014, Ms. Parker has served on the board of directors of IMPEL Pharmaceuticals Inc., a publicly-traded pharmaceutical company and Sangamo Therapeutics, Inc., a publicly-traded genomic therapies company. Ms. Parker also currently serves on the board of directors of various private companies. Previously, Ms. Parker served on the board of directors of Achieve Life Sciences, Inc., a publicly-traded pharmaceutical company, from August 2017 to May 2021, and Armata Pharmaceuticals, Inc. (formerly C3J Therapeutics, Inc.), a publicly-traded biotechnology company, from May 2019 to December 2020. Ms. Parker obtained a B.A. in Slavic Language & Literature and an M.B.A. in Finance and International Business from the University of Washington.
Donna Ambrosino, MD
Board Director
Dr. Donna Ambrosino is a renowned scientific leader for vaccine development having previously served as Chief Executive Officer at Nosocomial Vaccine Corporation and the first Chief Executive Officer of MassBiologics, University of Massachusetts Medical School. At MassBiologics, Dr. Ambrosino invented and developed multiple monoclonal antibodies in infectious disease with two now being commercial products (Zinplava and Rabishield).
Dr. Ambrosino was also a Professor of Pediatrics at University of Massachusetts Medical School, and Associate Professor of Pediatrics at the Dana-Farber Cancer Institute and Children’s Hospital, Harvard Medical School. At Harvard Medical School she was a National Institutes of Health-funded researcher.
She now serves on multiple Scientific Advisory Boards and Board of Directors as well as previously serving as Advisor to WHO, CEPI, and the Gates Foundation
Yves Leurquin, Eng, MS
Board Director
Yves Leurquin leads Inventprise with a focus on partnerships, capital formation and structural growth. Before joining Inventprise, Yves Leurquin was Global Head of Pricing and Tender Management for Takeda’s Vaccine Business Unit. He joined the newly created Takeda Vaccine Business Unit at its inception where he led the Asia Pacific Region and then the European Region. Yves also held corporate board positions, at Takeda Vaccine Internationals. Additionally, Yves prior experience included EVP International and Government Affairs at Johnson & Johnson (Crucell) with oversight of relations with the United Nations organizations as well as business responsibility for Latin America, Middle East, Africa and Asia where he led a multi-functional team of marketing, sales and government affairs professionals generating two third of the group’s vaccine revenue. While at J&J Yves Leurquin organized the development and international launch of the first liquid Penta vaccine, winning supply contracts with UNICEF and PAHO and rapidly achieving a dominant market share. Prior to joining Johnson &Johnson, Yves was with the vaccine division of GlaxoSmithKline, holding progressively responsible positions over a 10-year tenure
Andrew Farnum
Board Director
Andrew Farnum is the CEO of Variant Bio, a company developing therapies by studying the genes of people with exceptional health-related traits. Variant has dozens of genomic research partnerships on six continents, working hand in hand with communities that have not previously participated in genomic research. Before Variant, Andrew was the Director of the Gates Foundation’s Strategic Investment Fund, where he led the foundation’s $2 billion investment program and chaired the foundation’s investment committee. Earlier, Andrew was an investor and investment banker at TPG and Goldman Sachs. Andrew has a master’s degree in international development from the Harvard Kennedy School and an AB in molecular biology from Princeton University.
Scientific Advisory Board
Christian W. Mandl, MD, PhD
Chair, Strategic Advisory Board
Christian W. Mandl is a consultant for industrial, academic and non-profit organizations on translational aspects of vaccines, cancer immunotherapy and global health.
His engagement with the health care industry and public health organizations includes roles as Co-founder and Chair, Scientific Advisory Board for Tiba Biotech (Boston, USA), Senior Advisor at Adjuvant Capital (New York, USA), and Chair, Scientific Advisory Group for the International Vaccine Institute (Seoul, Korea). Previously he was the Senior Vice President of RNA Research for VIR Bio (San Francisco, USA), and the Chair of the Scientific Advisory Board for Themis Bioscience (Vienna, Austria). Until 2015, he was Global Head of Research, Early and Exploratory Clinical Development at Novartis Vaccines, where he led a global team of more than 300 discovery and clinical researchers developing a broad range of viral and bacterial vaccines, adjuvants and delivery platforms including the self-amplifying RNA technology (SAMÒ), which he initiated inspired by his previous academic research.
Prior to joining Novartis in 2008, Christian was Professor of Virology and Assistant Head of the Clinical Institute of Virology at Medical University of Vienna, Austria. He has authored more than 100 scientific publications and is an inventor on patents for vaccine and RNA technologies.
He holds a MSc in Biochemistry (1985) from Penn State University, a PhD in Biochemistry (1988) and a MD (1993) from University of Vienna, as well as a Certification as a Medical Specialist in Virology (1999) from the Austrian Medical Association.
Subhash Kapre, PhD
Advisor
Inventprise’s Founder and Executive Chairman of the Board is Subhash Kapre, PhD. His experience encompasses multiple senior executive vice president positions at Serum Institute of India Pvt. Ltd. (SIIPL), which measured by volume, is the world’s largest vaccine manufacturer. During his four-decade tenure at SIIPL, Subhash held multiple functional leadership positions in R&D, manufacturing, and vaccine discovery.
Subhash is a thought leader in rDNA technology, an internationally renowned expert in both bacterial and viral vaccines and has led certification of WHO- Prequalification (regulatory approval) for large scale manufacturing. He held board positions at Akorn, and Serum Institute of India, where he was board, executive director.
Subhash has a history of driving multiple vaccines from discovery, into development and through licensure for infectious diseases, including MenAfriVac® and Pneumosil®, conjugate vaccines which together will represent over 500M aggregate doses delivered by 2022. Subhash holds over 70 patents and founded Inventprise in 2012 to continue his career long mission to provide vaccines for those most in need.
Ralf Clemens, MD, PhD
Advisor
Dr. Ralf Clemens has held executive positions in several leading multinational corporations, such as GSK, Novartis Vaccines, and Takeda, and has developed and brought to licensure more than 25 different vaccines globally.
Dr. Clemens is currently a member of the Board of Trustees of the International Vaccine Institute (IVI), a leading global vaccinology organization initiated by the United Nations Development Programme, a Member of the Selection Committee of Global Health Innovative Technology (GHIT) Fund from Japan, and an external Scientific Advisor to the Bill & Melinda Gates Foundation. He is the author of more than 200 publications and 250 presentations in the fields of vaccines, immunization, and tropical medicine.
Donna Ambrosino, MD
Advisor
Dr. Donna Ambrosino is a renowned scientific leader for vaccine development having previously served as Chief Executive Officer at Nosocomial Vaccine Corporation and the first Chief Executive Officer of MassBiologics, University of Massachusetts Medical School. At MassBiologics, Dr. Ambrosino invented and developed multiple monoclonal antibodies in infectious disease with two now being commercial products (Zinplava and Rabishield).
Dr. Ambrosino was also a Professor of Pediatrics at University of Massachusetts Medical School, and Associate Professor of Pediatrics at the Dana-Farber Cancer Institute and Children’s Hospital, Harvard Medical School. At Harvard Medical School she was a National Institutes of Health-funded researcher.
She now serves on multiple Scientific Advisory Boards and Board of Directors as well as previously serving as Advisor to WHO, CEPI, and the Gates Foundation
Dr. Kathleen Neuzil, MD
Advisor
Dr. Kathleen Neuzil is the Myron M. Levine Professor in Vaccinology, Professor of Medicine and Pediatrics, and the Director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine. She is an internationally recognized research scientist and advocate in the field of vaccinology. Throughout her career, Dr. Neuzil has conducted clinical and epidemiologic studies on vaccine-preventable diseases, yielding high-profile publications that inform policy decisions and public health actions. Dr. Neuzil’s work has spanned dozens of low-resource countries with multiple vaccines, including influenza, rotavirus, human papillomavirus, Japanese encephalitis, typhoid conjugate vaccines, and most recently, COVID-19 vaccines. Dr. Neuzil is central to the domestic and global response to COVID. As a co-PI of the NIH-funded Leadership Group for the Vaccine and Treatment Evaluation Unit network, Dr. Neuzil is part of the strategic team evaluating COVID vaccines and therapeutics in the US. Dr. Neuzil also directs TyVAC, the Typhoid Vaccine Acceleration Consortium, with the goal to accelerate the introduction of typhoid conjugate vaccines into low-resource countries. She has more than 300 scientific publications, reviews and book chapters on vaccines and infectious diseases. Dr. Neuzil’s research capabilities are complemented by 20 years of involvement in domestic and international policy, including past membership on the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices. She is a member of the World Health Organization Strategic Advisory Group of Experts on Immunization and of the prestigious National Academy of Medicine.
Peter Dull, MD
Advisor
Peter is Deputy Director for Integrated Clinical Vaccine Development within the Global Health Division at the Bill and Melinda Gates Foundation. In this role he provides technical and strategic guidance on clinical development to the foundation’s program strategy teams and external partners. In addition, he leads the foundation’s vaccine development activities for HPV vaccines, including efforts on new product development and reduced dose schedules. He joined the foundation after 10 years at Novartis Vaccines where he was the Clinical Franchise Head for Meningitis and Sepsis Vaccines, leading the clinical development global licensure of MenACWY-CRM (Menveo) and 4CMenB (Bexsero). During the Covid-19 pandemic, in addition to providing direct support for grantees developing new COVID-19 vaccines, he co-led with CEPI partners the COVAX Clinical SWAT team providing product-agnostic support to developers to accelerate vaccine licensure and WHO pre-qualification with an LMIC focus. Prior to joining Novartis, he was an Epidemic Intelligence Service officer in the Meningitis and Special Pathogens Branch at the US Centers for Disease Control and completed subspecialty training in infectious diseases at Emory University.